Avid Bioservices Stock Performance
| CDMO Stock | USD 12.46 0.02 0.16% |
On a scale of 0 to 100, Avid Bioservices holds a performance score of 16. The firm shows a Beta (market volatility) of 0.25, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Avid Bioservices' returns are expected to increase less than the market. However, during the bear market, the loss of holding Avid Bioservices is expected to be smaller as well. Please check Avid Bioservices' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Avid Bioservices' price patterns will revert.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Avid Bioservices are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, Avid Bioservices displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.0805 | Five Day Return (0.08) | Year To Date Return 0.97 | Ten Year Return 38.84 | All Time Return (86.46) |
Last Split Factor 1:7 | Dividend Date 2017-07-10 | Last Split Date 2017-07-10 |
1 | SEKISUI Completes 15.7 Million Expansion in cGMP Biopharma CDMO Capacity | 11/14/2024 |
2 | Avid Bioservices, Inc. Shares Bought by Parkman Healthcare Partners LLC | 12/04/2024 |
3 | Disposition of 26756 shares by Alegria Esther M. of Avid Bioservices subject to Rule 16b-3 | 12/13/2024 |
4 | RTI Surgical Transforms into Evergen, a Leading CDMO in Regenerative Medicine | 12/17/2024 |
5 | Disposition of 75000 shares by Green Nicholas Stewart of Avid Bioservices at 12.3122 subject to Rule 16b-3 | 12/20/2024 |
6 | Acquisition by Green Nicholas Stewart of 119973 shares of Avid Bioservices subject to Rule 16b-3 | 12/24/2024 |
7 | Disposition of 88236 shares by Green Nicholas Stewart of Avid Bioservices at 12.22 subject to Rule 16b-3 | 12/26/2024 |
8 | Acquisition by Green Nicholas Stewart of 1755 shares of Avid Bioservices at 6.052 subject to Rule 16b-3 | 12/31/2024 |
9 | Cell Therapy and Gene Therapy CDMO Market to Reach USD 11.11 Billion by 2030 Discover Growth Trends and Insights Valuates Reports | 01/03/2025 |
10 | BioHarvest Issues Shareholder Letter and Provides Corporate Update | 01/08/2025 |
11 | Disposition of 200 shares by Richard Richieri of Avid Bioservices at 12.37 subject to Rule 16b-3 | 01/10/2025 |
12 | La fusin de BioCina y NovaCina fortalece la industria global de CDMO | 01/13/2025 |
13 | Vetter introduces the next evolution of the V-OVS syringe closure system | 01/14/2025 |
14 | Avid Bioservices, Inc. Insider Sells 28,240.71 in Stock | 01/16/2025 |
15 | Acquisition by Carleone Joseph of 8147 shares of Avid Bioservices subject to Rule 16b-3 | 01/24/2025 |
| Begin Period Cash Flow | 38.9 M |
Avid |
Avid Bioservices Relative Risk vs. Return Landscape
If you would invest 1,027 in Avid Bioservices on November 1, 2024 and sell it today you would earn a total of 217.00 from holding Avid Bioservices or generate 21.13% return on investment over 90 days. Avid Bioservices is currently generating 0.3381% in daily expected returns and assumes 1.6535% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Avid, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Avid Bioservices Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avid Bioservices' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Avid Bioservices, and traders can use it to determine the average amount a Avid Bioservices' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2045
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CDMO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.65 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.34 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 16 84% of assets perform better |
Based on monthly moving average Avid Bioservices is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avid Bioservices by adding it to a well-diversified portfolio.
Avid Bioservices Fundamentals Growth
Avid Stock prices reflect investors' perceptions of the future prospects and financial health of Avid Bioservices, and Avid Bioservices fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avid Stock performance.
| Return On Equity | -1.16 | ||||
| Return On Asset | -0.0305 | ||||
| Profit Margin | (1.01) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 967.17 M | ||||
| Shares Outstanding | 63.96 M | ||||
| Price To Earning | 10.76 X | ||||
| Price To Book | 17.74 X | ||||
| Price To Sales | 5.59 X | ||||
| Revenue | 139.91 M | ||||
| Gross Profit | 8.93 M | ||||
| EBITDA | (11.48 M) | ||||
| Net Income | (140.75 M) | ||||
| Cash And Equivalents | 115.14 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 207.83 M | ||||
| Debt To Equity | 1.02 % | ||||
| Current Ratio | 1.93 X | ||||
| Book Value Per Share | 0.96 X | ||||
| Cash Flow From Operations | 10.95 M | ||||
| Earnings Per Share | (2.41) X | ||||
| Market Capitalization | 795.7 M | ||||
| Total Asset | 336.56 M | ||||
| Retained Earnings | (571.87 M) | ||||
| Working Capital | 33.44 M | ||||
| Current Asset | 25.65 M | ||||
| Current Liabilities | 10.9 M | ||||
About Avid Bioservices Performance
By examining Avid Bioservices' fundamental ratios, stakeholders can obtain critical insights into Avid Bioservices' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Avid Bioservices is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 75.25 | 98.93 | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.06) | (0.07) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (2.66) | (2.53) |
Things to note about Avid Bioservices performance evaluation
Checking the ongoing alerts about Avid Bioservices for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avid Bioservices help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 139.91 M. Net Loss for the year was (140.75 M) with profit before overhead, payroll, taxes, and interest of 8.93 M. | |
| Avid Bioservices has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Carleone Joseph of 8147 shares of Avid Bioservices subject to Rule 16b-3 |
- Analyzing Avid Bioservices' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avid Bioservices' stock is overvalued or undervalued compared to its peers.
- Examining Avid Bioservices' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avid Bioservices' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avid Bioservices' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avid Bioservices' stock. These opinions can provide insight into Avid Bioservices' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avid Bioservices. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Avid Stock, please use our How to Invest in Avid Bioservices guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avid Bioservices. If investors know Avid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avid Bioservices listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (2.41) | Revenue Per Share | Quarterly Revenue Growth 0.065 | Return On Assets |
The market value of Avid Bioservices is measured differently than its book value, which is the value of Avid that is recorded on the company's balance sheet. Investors also form their own opinion of Avid Bioservices' value that differs from its market value or its book value, called intrinsic value, which is Avid Bioservices' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avid Bioservices' market value can be influenced by many factors that don't directly affect Avid Bioservices' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avid Bioservices' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avid Bioservices is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avid Bioservices' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.